Physician profile
Barry Jay Feldman
NPI 1598764276
$12,364.51
in general payments reported to CMS, 2019-2025
39 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,603 · 2020: $58.69 · 2021: $490 · 2022: $2,139 · 2023: $1,670 · 2024: $3,552 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,324 · Consulting Fee: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,324.35 |
| Consulting Fee | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,176.18 | 2019 | |
| Altathera Pharmaceuticals LLC | $1,766.09 | 2023-2024 | Sotalol Hydrochloride |
| Novartis Pharmaceuticals Corporation | $858.67 | 2021-2025 | |
| Boston Scientific Corporation | $628.08 | 2019-2025 | Watchman Flx, Watchman Access System, Avvigo Guidance System |
| Amgen INC. | $508.55 | 2020-2025 | Repatha, Repatha |
| Abbott Laboratories | $492.71 | 2021-2025 | Aveir, Jot Dx, Confirm Rx |
| Philips North America LLC | $483.44 | 2023-2025 | (Ck4) Mcot, Event, (Ck6) Holter |
| Alnylam Pharmaceuticals INC. | $471.36 | 2022-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $444.74 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.75 | 2021-2024 | Jardiance |
| Pfizer INC. | $407.46 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $402.44 | 2021-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $332.46 | 2020-2024 | Lifevest |
| Heartflow, INC. | $292.44 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $233.40 | 2021-2025 | Farxiga, Wainua, Brilinta |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $212.65 | 2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax |
| Kiniksa Pharmaceuticals International, Plc | $205.49 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $203.86 | 2022-2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $199.15 | 2022-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $155.30 | 2022-2025 | |
| Cvrx, INC. | $148.48 | 2022-2023 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $148.23 | 2024 | Optimizer |
| Lantheus Medical Imaging, INC. | $134.04 | 2022 | |
| Akcea Therapeutics, INC. | $121.83 | 2019 | |
| Siemens Medical Solutions USA, INC. | $121.76 | 2024 | Magnetom Sola |
| Esperion Therapeutics, INC. | $117.36 | 2022-2025 | Nexletol |
| Medtronic, INC. | $114.32 | 2021 | |
| Scpharmaceuticals INC. | $114.18 | 2023-2024 | |
| Biosense Webster, INC. | $89.23 | 2019 | |
| Novo Nordisk INC | $77.13 | 2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $72.99 | 2024 | Opsumit, Uptravi |
| Abiomed | $65.31 | 2024-2025 | Impella |
| Genzyme Corporation | $21.71 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $19.12 | 2022 | |
| Edwards Lifesciences Corporation | $18.89 | 2025 | Pascal |
| Chiesi USA, INC. | $17.99 | 2023 | Kengreal |
| Biotronik INC. | $17.26 | 2019 | |
| Amarin Pharma, INC. | $15.96 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.